MARKET NEWS

INmune Bio, Inc. Announces Research Collaboration With Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer
Sterling Pharma Solutions Expands Early Phase Development Capabilities at Cary, NC, Facility
Monte Rosa Therapeutics & Yeda Announce License & Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed With Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein

  FEATURED EDITORIAL

  COMPANY PROFILE

SGS Health Science is a leading contract service organization offering high quality analytical development, biologics characterization, utilities qualification, and quality control testing for over 40 years. Backed by a global network of testing facilities, we can help you to reduce risks, shorten time to market and demonstrate the quality and safety of your products. Our facilities utilize cutting-edge techniques and technologies and are staffed by knowledgeable and experienced personnel who stay abreast on the most recent developments in the field. Our aim is to provide a comprehensive package to support clients from molecule to market, through research, clinical trials product development, quality control testing, manufacture and supply. Whether you need a partner to handle all your testing needs or just an extra hand when your in-house capabilities are restricted, SGS is flexible to meet your needs. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia & Dementia with Lewy Bodies

Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia & Dementia with Lewy Bodies

Athira Pharma, Inc. recently announced patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson’s disease dementia and Dementia with Lewy bodies….

Biomea Fusion Announces First Patient Dosed

Biomea Fusion Announces First Patient Dosed

Biomea Fusion, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with….

 FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

 FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. recently announced the US FDA has cleared MindMed’s Investigational New Drug application, allowing the company’s Phase 2b dose-optimization trial of….

Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics, Inc. recently announced the initiation of the Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients, with trial sites open for….

Starton Therapeutics Successfully Demonstrates Continuous Drug Delivery of Lenalidomide From a Transdermal Patch in an In Vivo Nonclinical Study With STAR-LLD

Starton Therapeutics Successfully Demonstrates Continuous Drug Delivery of Lenalidomide From a Transdermal Patch in an In Vivo Nonclinical Study With STAR-LLD

Starton Therapeutics Inc. recently announced it successfully obtained promising results in a non-GLP rabbit pharmacokinetic (PK) and skin irritation study of….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 9 – Injection Devices
February 16 – Formulation Development